Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

zipalertinib (CLN-081)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cullinan Therap, Otsuka, ZAI Lab

Drug class:

EGFR inhibitor, Tyrosine kinase inhibitor

Related drugs:

‹

Tyrosine Kinase inhibitors (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

Tyrosine Kinase inhibitors (0)

›

EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B
HER-2 V777L + EGFR L858R	Lung Cancer	HER-2 V777L + EGFR L858R	Lung Cancer	CLN-081 Resistant: D – Preclinical CLN-081 Resistant : D	CLN-081 Resistant: D – Preclinical CLN-081 Resistant : D